ZFYVE27 Antibody

What is ZFYVE27 and why is it significant in research?

ZFYVE27, also known as Protrudin, is a protein involved in autophagy and vesicular trafficking processes within cells. It plays a crucial role in regulating the formation and transport of vesicles, particularly in the context of autophagy and intracellular signaling pathways. The significance of ZFYVE27 in research stems from its implication in various diseases, including neurodegenerative disorders and cancer. It promotes neurite formation by facilitating directional membrane trafficking in neurons. Dysfunction of this protein has been linked to hereditary spastic paraplegia, making it an important target for neurological research . Understanding ZFYVE27's functions provides valuable insights into mechanisms of disease pathology and potential therapeutic targets for neurodegenerative conditions .

What are the common synonyms and identifiers for ZFYVE27?

When searching literature and databases for ZFYVE27, researchers should be aware of several synonyms:

• Protrudin (most common alternative name)

• SPG33 (related to its role in hereditary spastic paraplegia)

• FLJ32919

• RP11-459F3.2

• Zinc finger FYVE domain-containing protein 27

These alternative names are important to include in literature searches to ensure comprehensive results. The protein has a calculated molecular weight of approximately 45.843 kDa, which is useful information when verifying antibody specificity in Western blot applications .

What are the key structural features of ZFYVE27 protein?

ZFYVE27 contains several important structural domains:

• Multiple transmembrane domains that anchor it to cellular membranes

• A Rab11-binding domain that facilitates interaction with this important trafficking regulator

• A lipid-binding FYVE finger domain that mediates membrane association

• Several hydrophobic regions (HR), with HR3 (amino acids 185-207) being particularly important for oligomerization

• A coiled-coil region in the C-terminus that helps stabilize oligomeric structures

These structural features are critical for ZFYVE27's function in promoting neurite formation and directional membrane trafficking. The HR3 region has been identified as particularly important for the protein's ability to form oligomers, which appears necessary for its biological functions .

What types of ZFYVE27 antibodies are commonly used in research?

The most common ZFYVE27 antibodies available for research are rabbit polyclonal antibodies. These antibodies are typically generated using recombinant proteins or peptide sequences from human ZFYVE27. For example:

• Polyclonal antibodies generated against amino acids 217-411 of human ZFYVE27 (NP_653189.3)

• Polyclonal antibodies raised against E.coli-derived human ZFYVE27 recombinant protein (Position: L212-K411)

These polyclonal antibodies typically exhibit reactivity against human ZFYVE27, with some cross-reactivity to mouse and rat orthologs, making them versatile tools for comparative studies across species .

Which applications are ZFYVE27 antibodies validated for?

ZFYVE27 antibodies have been validated primarily for:

• Western blot (WB): The most common application, where these antibodies can detect the approximately 46 kDa ZFYVE27 protein in cell lysates.

• Enzyme-Linked Immunosorbent Assay (ELISA): Used for quantitative analysis of ZFYVE27 levels in samples.

When selecting an antibody, researchers should verify the validation status for their specific application. Most commercial antibodies provide validation data showing specific bands at the expected molecular weight in positive control cell lines like DU145 .

What are the recommended working dilutions for different applications?

Based on the available research data, the following working dilutions are recommended:

These ranges provide starting points for optimization. Researchers should perform antibody titration experiments to determine the optimal concentration for their specific experimental conditions, sample types, and detection methods .

How should ZFYVE27 antibodies be stored and handled for optimal activity?

To maintain antibody integrity and activity:

• Store concentrated antibody stocks at -20°C for long-term storage (up to 12 months from the date of receipt).

• For medium-term storage (up to 6 months), store reconstituted antibodies at 2-8°C.

• Avoid repeated freeze-thaw cycles which can denature antibodies and reduce binding affinity.

• Prepare working dilutions fresh before use whenever possible.

• If antibodies are supplied in glycerol formulations (e.g., 50% glycerol with PBS, 0.02% NaN₃, and 1 mg BSA), mix thoroughly but gently before aliquoting or use.

Following these storage guidelines helps preserve antibody specificity and sensitivity for experimental applications .

What positive controls are recommended for ZFYVE27 antibody validation?

For validating ZFYVE27 antibodies, researchers should consider:

• DU145 cell line: Documented to express detectable levels of ZFYVE27 and recommended as a positive control for Western blot applications .

• Human brain tissue lysates: Since ZFYVE27 plays important roles in neurons and has been linked to hereditary spastic paraplegia, brain tissue represents a physiologically relevant positive control.

• Recombinant ZFYVE27 protein: Can serve as a positive control, particularly useful when troubleshooting issues with endogenous protein detection.

Including appropriate positive controls is essential for confirming antibody specificity and proper experimental conditions .

How does ZFYVE27 oligomerization affect antibody binding and experimental design?

ZFYVE27 forms oligomeric structures, primarily dimers and tetramers, which has important implications for antibody-based experiments:

• Epitope accessibility: In oligomeric forms, certain epitopes may be masked or structurally altered, potentially affecting antibody recognition. This is particularly relevant for antibodies targeting regions involved in oligomerization, such as the HR3 domain (amino acids 185-207).

• Sample preparation: Denaturing conditions (like SDS-PAGE for Western blot) will disrupt oligomeric structures, potentially exposing epitopes that might be hidden in native conditions. Conversely, non-denaturing techniques (like co-immunoprecipitation) preserve these oligomeric interactions.

• Experimental approach selection: To study ZFYVE27 oligomers specifically, researchers might need techniques like sucrose gradient centrifugation, which has been successfully used to demonstrate the oligomeric nature of ZFYVE27 .

When designing experiments, researchers should consider whether they wish to detect total ZFYVE27 or specifically study its oligomeric forms, as this will influence antibody selection and experimental conditions .

What are the challenges in studying ZFYVE27 protein interactions using antibodies?

Studying ZFYVE27 interactions presents several challenges:

• Multiple interaction domains: ZFYVE27 contains several domains involved in protein-protein interactions, including the HR3 region crucial for self-interaction. Antibodies targeting these regions may interfere with or disrupt natural interactions.

• Methodological discrepancies: Research has shown discrepancies between interaction results obtained via co-immunoprecipitation versus yeast two-hybrid assays. For example, deletion of the HR3 region abolished ZFYVE27 self-interaction in yeast two-hybrid but not completely in co-immunoprecipitation experiments .

• Quaternary structure complexity: ZFYVE27 forms complex quaternary structures (dimers/tetramers), similar to other FYVE proteins like Hrs and EEA1. This complexity makes it challenging to interpret interaction data.

To address these challenges, researchers should employ multiple complementary approaches (e.g., co-IP, Y2H, FRET) and carefully select antibodies that do not target known interaction interfaces unless specifically studying those interactions .

How can researchers distinguish between different oligomeric forms of ZFYVE27?

To differentiate between monomeric, dimeric, and higher-order oligomeric forms of ZFYVE27:

• Sucrose gradient centrifugation: This technique has been successfully used to demonstrate that ZFYVE27 oligomerizes into dimer/tetramer forms. Different oligomeric states sediment at different rates in the gradient.

• Native PAGE followed by Western blotting: Unlike denaturing SDS-PAGE, native PAGE preserves protein complexes and can separate different oligomeric forms based on size and charge.

• Chemical crosslinking: Treatment with crosslinking agents before SDS-PAGE can "freeze" protein complexes in their native oligomeric state for subsequent analysis.

• Size exclusion chromatography: This can separate proteins based on their hydrodynamic radius, allowing differentiation between monomers and various oligomeric forms.

These approaches provide complementary data on the quaternary structure of ZFYVE27 and help elucidate how oligomerization relates to its biological functions .

What experimental approaches best capture ZFYVE27's role in neurite extension?

To effectively study ZFYVE27's role in neurite extension:

• Live-cell imaging with fluorescently tagged ZFYVE27: This allows visualization of ZFYVE27 dynamics during neurite formation and extension.

• Domain-specific mutations: Generating constructs with mutations in specific domains (particularly HR3) helps determine which regions are essential for neurite promotion.

• Co-localization studies: Using ZFYVE27 antibodies alongside markers for vesicular trafficking components (e.g., Rab11) can reveal how ZFYVE27 directs membrane addition during neurite extension.

• Functional rescue experiments: In cells where ZFYVE27 has been knocked down, reintroducing wild-type versus mutant forms can demonstrate which domains are required for neurite extension.

• Interaction studies with spastin: Since ZFYVE27 was originally identified as an interacting partner of spastin (the protein most frequently mutated in hereditary spastic paraplegia), studying this interaction provides insight into disease mechanisms .

What are common issues when using ZFYVE27 antibodies in Western blot?

Researchers may encounter several challenges when detecting ZFYVE27 in Western blot:

• Multiple bands: ZFYVE27 may appear as multiple bands due to post-translational modifications or proteolytic processing. To address this:

  • Include appropriate positive controls with known ZFYVE27 expression

  • Consider using gradient gels for better separation

  • Verify bands using knockdown/knockout controls

• High background: This common issue can be addressed by:

  • Optimizing blocking conditions (try different blocking agents like 5% BSA or milk)

  • Increasing washing stringency (longer washes or higher detergent concentration)

  • Further diluting the primary antibody

  • Using more specific secondary antibodies

• Weak signal: To improve detection:

  • Increase protein loading (up to 50 μg total protein)

  • Optimize transfer conditions for high molecular weight proteins

  • Use more sensitive detection systems (enhanced chemiluminescence or fluorescent secondaries)

  • Decrease antibody dilution within the recommended range (1:500 instead of 1:2000)

How can cross-reactivity concerns be addressed when studying ZFYVE27?

To minimize cross-reactivity issues:

• Validation with specific controls:

  • Use ZFYVE27 knockout or knockdown samples as negative controls

  • Include overexpression systems as positive controls

  • Compare results with multiple antibodies targeting different epitopes

• Epitope considerations:

  • Check if the antibody's immunogen sequence has homology to other proteins

  • For polyclonal antibodies targeting amino acids 217-411 or L212-K411, verify this region's specificity using bioinformatic tools

• Species-specific optimization:

  • Although many ZFYVE27 antibodies react with human, mouse, and rat orthologs, optimization may be needed when switching between species

  • Adjust dilutions and incubation conditions when working with different species samples

What sample preparation methods are optimal for detecting ZFYVE27 in different cellular compartments?

ZFYVE27 localizes to various cellular compartments including cell membranes and cell projections. Optimal detection requires specific sample preparation:

• Total cell lysates:

  • Use RIPA buffer supplemented with protease inhibitors

  • Sonicate briefly to shear DNA and reduce sample viscosity

  • Centrifuge at high speed (≥12,000 × g) to remove insoluble material

• Membrane-enriched fractions:

  • Use gentler non-ionic detergents (e.g., 1% NP-40 or Triton X-100)

  • Consider sucrose gradient fractionation to separate different membrane components

  • Include steps to remove cytosolic proteins, which can mask membrane-associated signals

• Neurite/protrusion preparations:

  • Consider specialized methods for isolating cellular projections

  • In neuronal cultures, use microdissection techniques to enrich for growth cones

Each preparation method should be optimized based on the specific research question and cellular compartment of interest .

How should researchers approach epitope masking issues with ZFYVE27 antibodies?

Epitope masking can occur due to protein-protein interactions, post-translational modifications, or conformational changes. To address this:

• Sample treatment strategies:

  • Heat samples at 95-100°C in reducing buffer containing SDS and DTT or β-mercaptoethanol to fully denature proteins

  • For native conditions, try different detergents that may disrupt specific interactions while preserving others

  • Consider mild fixation techniques that preserve epitope accessibility

• For particularly challenging detection:

  • Try antigen retrieval methods adapted from immunohistochemistry

  • Test alternate epitope exposure methods like limited proteolysis

  • Consider specialized membrane preparation techniques that maintain protein orientation

• When studying ZFYVE27 oligomers:

  • Remember that the HR3 region (amino acids 185-207) is critical for oligomerization

  • Antibodies targeting this region may have differential access depending on oligomerization state

  • Use complementary approaches like co-immunoprecipitation with antibodies targeting different epitopes